CT-P13: design, development, and place in therapy

References

• SolbergICLygrenIJahnsenJIBSEN Study GroupClinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)Scand J Gastroenterol200944 431 44019101844
   PubMed Web of Science ®Google Scholar
• SolbergIVatnMHoieOIBSEN Study GroupClinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up studyClin Gastroenterol Hepatol20075 1430 143818054751
   PubMed Web of Science ®Google Scholar
• DaneseSVuittonLPeyrin-BirouletLBiological agents for IBD: practical insightsNat Rev Gastroenterol Hepatol201512 537 54526284562
   PubMed Web of Science ®Google Scholar
• AnneseVDuricovaDGower-RousseauCJessTLangholzEImpact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the Epidemiology Committee of ECCOJ Crohns Colitis2016102 216 22526520163
   PubMed Web of Science ®Google Scholar
• ScheinbergMAKayJThe advent of biosimilar therapies in rheumatology – “O brave new world”Nat Rev Rheumatol20128 430 43622664834
   PubMed Web of Science ®Google Scholar
• JhaAUptonADunlopWCAkehurstRThe budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countriesAdv Ther2015328 742 75626343027
   PubMed Web of Science ®Google Scholar
• JahnsenJClinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patientsTherap Adv Gastroenterol201693 322 329
   PubMed Web of Science ®Google Scholar
• WeiseMBielskyMCDe SmetKBiosimilars: what clinicians should knowBlood201212026 5111 511723093622
   PubMed Web of Science ®Google Scholar
• SchneiderCKVleminckxCGravanisISetting the stage for biosimilar monoclonal antibodiesNat Biotechnol201230 1179 118523222783
   PubMed Web of Science ®Google Scholar
• World Health OrganizationExpert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products2009 Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdfAccessed February 28, 2016
   Google Scholar
• U. S. Food and Drugs Administration [webpage on the Internet]Demonstration of comparability of human biological products, including therapeutic biotechnology-derived products Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122879.htmAccessed April 4, 2016
   Google Scholar
• International Conference on HarmonisationQ5E Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdfAccessed April 4, 2016
   Google Scholar
• US Food and Drug Administration [webpage on the Internet]Biosimilars2015 [cited Dec 7, 2015]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/BiosimilarsAccessed December 1, 2016
   Google Scholar
• European Medicines Agency [webpage on the Internet]Biosimilar medicines2015 [cited Dec 7, 2015]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000318.jspAccessed December 1, 2016
   Google Scholar
• Committee for Medicinal Products for Human Use, European Medicines AgencyGuideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. EMA/CHMP/BMWP/403543/20102012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdfAccessed September 4, 2013
   Google Scholar
• Health Products and Food Branch, Health CanadaGuidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs)2010 Available from: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/biosimilars-biosimilaires-eng.phpAccessed February 4, 2014
   Google Scholar
• U. S. Food and Drug AdministrationGuidance for industry: scientific considerations in demonstrating biosimilarity to a reference product (draft guidance)2012 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdfAccessed February 4, 2014
   Google Scholar
• EbbersHCBiosimilars: in support of extrapolation of indicationsJ Crohns Colitis201485 431 43524594005
   PubMed Web of Science ®Google Scholar
• WeiseMKurkiPWolff-HolzEBielskyMSchneiderCBiosimilars: the science of extrapolationBlood2014124 3191 319625298038
   PubMed Web of Science ®Google Scholar
• FeaganBGChoquetteDGhoshSThe challenge of indication extrapolation for infliximab biosimilarsBiologicals201442 177 18324962198
   PubMed Web of Science ®Google Scholar
• LemannMMaryJDuclosBInfliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trialGastroenterology2006130 1054 106116618399
   PubMed Web of Science ®Google Scholar
• ColombelJSandbornWReinischWGroupe d’Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID)Infliximab, azathioprine, or combination therapy for Crohn’s diseaseN Engl J Med2010362 1383 139520393175
   PubMed Web of Science ®Google Scholar
• PanaccioneRGhoshSMiddletonSCombination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitisGastroenterology2014146 392 400 e39324512909
   PubMed Web of Science ®Google Scholar
• HanauerSFeaganBLichtensteinGACCENT I Study GroupMaintenance infliximab for Crohn’s disease: the ACCENT I randomised trialLancet2002359 1541 154912047962
   PubMed Web of Science ®Google Scholar
• RutgeertsPSandbornWFeaganBInfliximab for induction and maintenance therapy for ulcerative colitisN Engl J Med2005353 2462 247616339095
   PubMed Web of Science ®Google Scholar
• Evaluate™ [webpage on the Internet]KFDA approves Remsima(TM) (infliximab), the world’s first antibody biosimilar [press release]Celltrion, Johnson & Johnson2012 [July 23]. Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=320129Accessed December 1, 2016
   Google Scholar
• European Medicines AgencyCommittee for Medicinal Products for Human Use (CHMP). Assessment report: Inflectra (infliximab)2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdfAccessed February 17, 2014
   Google Scholar
• Generics and biosimilars initiative online [webpage on the Internet]Biosimilars approved in South Korea2015 Available from: http://gabionline.net/Biosimilars/General/Biosimilars-approved-in-South-KoreaAccessed December 1, 2016
   Google Scholar
• Generics and biosimilars initiative online [webpage on the Internet]Biosimilars approved in Japan2015 Available from: http://gabionline.net/Biosimilars/General/Biosimilars-approved-in-JapanAccessed December 1, 2016
   Google Scholar
• INFLECTRA [prescribing information] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125544s000lbl.pdfAccessed April 11, 2016
   Google Scholar
• Health Canada [webpage on the Internet]Summary basis of decision for Remsima2014 Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/index-eng.phpAccessed February 28, 2016
   Google Scholar
• CADTHCADTH Canadian drug expert committee final recommendation: infliximab (Inflectra – Hospira Healthcare Corporation) Indications: Crohn Disease and Ulcerative Colitis2016 Available from: https://www.cadth.ca/sites/default/files/cdr/complete/SE0483_IBD_Inflectra-Oct-28-16.pdfAccessed December 1, 2016
   Google Scholar
• European Medicines AgencyCommittee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medici nal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues Draft2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdfAccessed February 17, 2014
   Google Scholar
• Appendix A PLANETAS study Ann Rheum Dis2013 Available from: http://ard.bmj.com.gate2.inist.fr/content/suppl/2013/05/16/annrheumdis-2012-203091.DC1/annrheumdis-2012-203091supp_appendixA.pdfAccessed July 11, 2013
   Google Scholar
• European Medicines AgencyCommittee for Medicinal Products for Human Use (CHMP). Assessment report: Inflectra (infliximab)2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdfAccessed February 17, 2014
   Google Scholar
• Summary basis of decision (SBD) for Remsima [webpage on the Internet]Health Canada Web site Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/index-eng.php. Published April 1, 2014Accessed April 9, 2014
   Google Scholar
• European Medicines AgencyCommittee for Medicinal Products for Human Use (CHMP). Assessment report: inflectra Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf. Published June 27, 2013Accessed December 2, 2014
   Google Scholar
• ParkWHrycajPJekaSA randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnn Rheum Dis201372 1605 161223687259
   PubMed Web of Science ®Google Scholar
• ParkWYooDHJaworskiJComparable long-term efficacy, as assessed by patient reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS studyArthritis Res Ther201618 2526795209
   PubMed Web of Science ®Google Scholar
• YooDHHrycajPMirandaPA randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnn Rheum Dis201372 1613 162023687260
   PubMed Web of Science ®Google Scholar
• YooDHRacewiczABrzezickiJA phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA studyArthritis Res Ther201618 8227038608
   PubMed Web of Science ®Google Scholar
• ParkWYooDHMirandaPEfficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension studyAnn Rheum Dis2017762 346 35427117698
   PubMed Web of Science ®Google Scholar
• YooDHProdanovicNJaworskiJEfficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension studyAnn Rheum Dis2017762 355 36327130908
   PubMed Web of Science ®Google Scholar
• AllezMKarmirisKLouisEReport of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspectsJ Crohn’s Colitis20104 355 36621122530
   PubMedGoogle Scholar
• GecseKBKhannaRvan den BrinkGRBiosimilars in IBD: hope or expectation?Gut201362 803 80723503043
   PubMed Web of Science ®Google Scholar
• Ben-HorinSHeapGQAhmadTThe immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Expert Rev Gastroenterol Hepatol20159Suppl 1 27 3426395532
   PubMedGoogle Scholar
• Van den BrandeJMKoehlerTCZelinkovaZPrediction of anti tumour necrosis factor clinical efficacy by realtime visualisation of apoptosis in patients with Crohn’s diseaseGut2007564 509 51717082252
   PubMed Web of Science ®Google Scholar
• TilgHMoschenAKaserAMode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseasesExpert Opin Biol Ther200777 1051 105917665993
   PubMed Web of Science ®Google Scholar
• ParkSKimYLeeJPost-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in KoreaExpert Rev Gastroenterol Hepatol20159 35 4426395533
   PubMedGoogle Scholar
• JungYSParkDIKimYHEfficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter studyJ Gastroenterol Hepatol20153012 1705 171225974251
   PubMed Web of Science ®Google Scholar
• KangYMoonHLeeSLimYKangHClinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case seriesDig Dis Sci201560 951 95625326115
   PubMed Web of Science ®Google Scholar
• KeilRWasserbauerMZádorováZClinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitisScand J Gastroenterol2016519 1062 106827002981
   PubMed Web of Science ®Google Scholar
• FarkasKRutkaMGolovicsPAEfficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitisJ Crohns Colitis20161011 1273 127827106537
   PubMed Web of Science ®Google Scholar
• MurphyCSugrueKMohamadJBiosimilar but not the sameJ Crohns Colitis20159Suppl 1 S331 S332 P505
   Google Scholar
• GecseKLovaszBFarkasKEfficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohortJ Crohn’s Colitis2015102 133 14026661272
   PubMedGoogle Scholar
• FarkasKRutkaMBalintAEfficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single centerExpert Opin Biol Ther201515 1257 126226134250
   PubMed Web of Science ®Google Scholar
• JahnsenJDetlieTVatnSRicanekPBiosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational studyExpert Rev Gastroenterol Hepatol20159 45 5226395534
   PubMedGoogle Scholar
• SchulzeKKoppkaNLutterFBrandhorstGSchreiberSHelwigUCT-P13(Inflectra™, Remsima™) monitoring in patients with inflammatory bowel diseaseBiologicals2016445 463 46627435444
   PubMed Web of Science ®Google Scholar
• Ben-HorinSYavzoriMBenharICross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar RemsimaGut2016657 1132 113825897019
   PubMed Web of Science ®Google Scholar
• FiorinoGManettiNArmuzziAThe PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilarInflamm Bowel Dis201723 233 24328092307
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drugs Administration [webpage on the Internet]Information on biosimilars Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htmAccessed March 25, 2016
   Google Scholar
• SieczkowskaJJarzębickaDBanaszkiewiczASwitching between infliximab originator and biosimilar in pediatric patients with inflammatory bowel disease: preliminary observationJ Crohn’s Colitis2015102 127 13226721942
   PubMedGoogle Scholar
• BraunJKudrinASwitching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public healthBiologicals2016444 257 26627117857
   PubMed Web of Science ®Google Scholar
• NikiphorouEKautiainenHHannonenPClinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational dataExpert Opin Biol Ther201515 1677 168326549204
   PubMed Web of Science ®Google Scholar
• FiorinoGManettiNArmuzziAThe PROSIT-BIO Cohort: A prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilarInflam Bowel Dis2017232 233 243
   PubMed Web of Science ®Google Scholar
• BioPharmaNorway to facilitate switch to biosimilars with $3m Remicade study http://www.biopharma-reporter.com/Markets-Regulations/Norwayto-facilitate-switch-to-biosimilars-with-3m-Remicadestudy2013Accessed January 7, 2016
   Google Scholar
• JørgensenKLB15 - Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: results from the 52-week randomized NOR-SWITCH trialAbstract presented at the United European Gastroenterology (UEG) Week meeting201615–19 OctoberVienna, Austria
   Google Scholar